Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Eli Lilly & Co. will pay Glenmark Pharmaceuticals $45 million up front and a possible $215 million more in milestones for a portfolio of molecules called transient receptor potential vanilloid subfamily 1 (TRPV1) antagonists, which are being developed in a range of pain indications. Lilly gains North American, European, and Japanese marketing rights to GRC 6211, Glenmark's lead TRPV1 antagonist, currently in Phase II trials to treat osteoarthritic pain. Mumbai-based Glenmark started out as a formulations and bulk drug manufacturing company but, in 2001, made a major push into drug discovery. It already has licensing deals with Merck KGaA and Forest Laboratories.
This article has been sent to the following recipient: